𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer

✍ Scribed by Joel B. Nelson; William Love; Joseph L. Chin; Fred Saad; Claude C. Schulman; Darryl J. Sleep; Jiang Qian; Joyce Steinberg; Michael Carducci; for the Atrasentan Phase 3 Study Group

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
244 KB
Volume
113
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 3 randomized controlled trial of
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer
✍ Michael A. Carducci; Fred Saad; Per-Anders Abrahamsson; David P. Dearnaley; Clau 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB 👁 1 views

## Abstract ## BACKGROUND. The objective of this study was to evaluate the efficacy and safety of atrasentan (Xinlay), a selective endothelin‐A receptor antagonist, in patients with metastatic hormone‐refractory prostate cancer (HRPC). ## METHODS. This multinational, double‐blind, placebo‐contro

Activity of second-line chemotherapy in
Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : Randomized phase 2 study of ixabepilone or mitoxantrone and prednisone
✍ Jonathan E. Rosenberg; Vivian K. Weinberg; W. Kevin Kelly; Dror Michaelson; Maha 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB

## Abstract ## BACKGROUND. This randomized, noncomparative, multicenter, clinical trial evaluated ixabepilone or mitoxantrone/prednisone (MP) as second‐line chemotherapy for taxane‐refractory, hormone‐refractory, prostate cancer (HRPC). ## METHODS. Patients with HRPC that progressed during or wi

Phase II trial of paclitaxel, estramusti
Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma
✍ David C. Smith; Christopher H. Chay; Rodney L. Dunn; Jude Fardig; Peg Esper; Kar 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 1 views

## Abstract ## BACKGROUND Preclinical data suggest that the combination of intravenous (i.v.) paclitaxel, carboplatin, oral etoposide, and oral estramustine (TEEC) has significant activity in patients with advanced, hormone‐refractory prostate carcinoma. The authors conducted this clinical trial t